These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24115129)

  • 1. Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women.
    Bala Y; Chapurlat R; Cheung AM; Felsenberg D; LaRoche M; Morris E; Reeve J; Thomas T; Zanchetta J; Bock O; Ghasem-Zadeh A; Djoumessi RM; Seeman E; Rizzoli R
    J Bone Miner Res; 2014 Feb; 29(2):380-8. PubMed ID: 24115129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
    Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
    Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodeling markers are associated with larger intracortical surface area but smaller trabecular surface area: a twin study.
    Bjørnerem Å; Ghasem-Zadeh A; Bui M; Wang X; Rantzau C; Nguyen TV; Hopper JL; Zebaze R; Seeman E
    Bone; 2011 Dec; 49(6):1125-30. PubMed ID: 21872686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
    Burghardt AJ; Kazakia GJ; Sode M; de Papp AE; Link TM; Majumdar S
    J Bone Miner Res; 2010 Dec; 25(12):2558-71. PubMed ID: 20564242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.
    Tournis S; Fakidari E; Dontas I; Liakou C; Antoniou J; Galanos A; Marketou H; Makris K; Katsalira K; Trovas G; Lyritis GP; Papaioannou N
    J Bone Miner Metab; 2014 Mar; 32(2):151-8. PubMed ID: 23700284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate reduces intracortical porosity in women with osteoporosis.
    Borah B; Dufresne T; Nurre J; Phipps R; Chmielewski P; Wagner L; Lundy M; Bouxsein M; Zebaze R; Seeman E
    J Bone Miner Res; 2010 Jan; 25(1):41-7. PubMed ID: 19580469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis.
    Zebaze R; Libanati C; McClung MR; Zanchetta JR; Kendler DL; Høiseth A; Wang A; Ghasem-Zadeh A; Seeman E
    J Bone Miner Res; 2016 Oct; 31(10):1827-1834. PubMed ID: 27082709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Bhattacharya RK; Sereika SM; Brufsky A; Vogel VG
    J Clin Endocrinol Metab; 2007 Jan; 92(1):131-6. PubMed ID: 17047022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
    Cohran V; Cassedy A; Hawkins A; Bean J; Heubi J
    J Pediatr Rehabil Med; 2013; 6(2):85-93. PubMed ID: 23803341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG; Sod E; Johnson T; Chines A
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women.
    Rønn SH; Harsløf T; Pedersen SB; Langdahl BL
    Eur J Endocrinol; 2016 Dec; 175(6):541-549. PubMed ID: 27625301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study).
    Tsai JN; Uihlein AV; Burnett-Bowie SM; Neer RM; Derrico NP; Lee H; Bouxsein ML; Leder BZ
    J Clin Endocrinol Metab; 2016 May; 101(5):2023-30. PubMed ID: 26964731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rheumatoid arthritis on volumetric bone mineral density and bone geometry, assessed by peripheral quantitative computed tomography in postmenopausal women treated with bisphosphonates.
    Tournis S; Samdanis V; Psarelis S; Liakou C; Antoniou J; Georgoulas T; Dontas I; Papaioannou N; Gazi S; Lyritis GP
    J Rheumatol; 2012 Jun; 39(6):1215-20. PubMed ID: 22467921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.
    Boutroy S; Bouxsein ML; Munoz F; Delmas PD
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6508-15. PubMed ID: 16189253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.